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AbstrACt
Introduction High morbidity and mortality rates of proven 
bacterial infection are the main reason for substantial use 
of intravenous antibiotics in neonates during the first week 
of life. In older children, intravenous-to-oral switch after 
48 hours of intravenous therapy has been shown to have 
many advantages and is nowadays commonly practised. 
We, therefore, aim to evaluate the effectiveness, safety and 
cost-effectiveness of an early intravenous-to-oral switch in 
neonates with a probable bacterial infection.
Methods and analysis We present a protocol for a 
multicentre randomised controlled trial assessing the 
non-inferiority of an early intravenous-to-oral antibiotic 
switch compared with a full course of intravenous 
antibiotics in neonates (0–28 days of age) with a probable 
bacterial infection. Five hundred and fifty patients will 
be recruited in 17 hospitals in the Netherlands. After 48 
hours of intravenous treatment, they will be assigned 
to either continue with intravenous therapy for another 
5 days (control) or switch to amoxicillin/clavulanic acid 
suspension (intervention). Both groups will be treated for 
a total of 7 days. The primary outcome will be bacterial 
(re)infection within 28 days after treatment completion. 
Secondary outcomes are the pharmacokinetic profile 
of oral amoxicillin/clavulanic acid, the impact on quality 
of life, cost-effectiveness, impact on microbiome 
development and additional yield of molecular techniques 
in diagnosis of probable bacterial infection.
Ethics and dissemination This study has been approved 
by the Medical Ethics Committee of the Erasmus Medical 
Centre. Results will be presented in peer-reviewed journals 
and at international conferences.
trial registration number NCT03247920
IntroduCtIon
Antibiotics are among the most prescribed 
drugs in the paediatric population. With 
increasing concerns regarding microbial 
resistance leading to potential multidrug 
resistant infections, antibiotic stewardship 
programmes have been developed. The main 
goal of these programmes is optimisation of 
the use of antibiotics. Moreover, unnecessary 
use should be reduced since antibiotics do 
interfere with the development of the gut 
microbiome in early stages of life, influencing 
the risk of developing several diseases such as 
asthma, diabetes and obesity later in life.1–3 
Initially started in adult population, these 
programmes have, since then, been imple-
mented in the paediatric field, starting with 
the formation of the Pediatric Committee on 
Antimicrobial Stewardship (AS) by the Paedi-
atric Infectious Diseases Society in 2010. One 
of the principles of AS is the appropriate 
and timely de-escalation of antibiotic use 
including a switch from parenteral to oral 
therapy in clinically well children. An early 
intravenous-to-oral switch leads to many 
advantages such as a reduction in hospital 
strengths and limitations of this study
 ► This study addresses an important clinical question 
regarding intravenous-to-oral antibiotic switch in 
neonatal care.
 ► The results of this study can be included in antibiotic 
stewardship programmes.
 ► A non-inferiority study design is used.
 ► The primary outcome assessment is challenging 
since it is impossible to state whether a new infec-
tion episode is a true reinfection since cultures of 
the first infection were sterile.
 ► Only probable bacterial infections are included in 
this study, thus, results cannot directly be applied to 
culture-proven infection.
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stay and associated health costs and is currently described 
in several guidelines.4 
However, oral switch therapy is not yet widely practised 
in neonates. When a bacterial infection is suspected, 
either based on maternal risk factors or subtle clinical 
symptoms, antibiotic therapy is immediately started. 
In the best-case scenario, symptoms disappear, inflam-
matory parameters are reassuring and cultures remain 
negative after which therapy can be stopped after 
36–48 hours. In some of the neonates (~1% of living 
births), the presence or absence of a bacterial infection 
cannot be established.5 They may have elevated inflam-
matory parameters and show clinical signs, although 
(blood) cultures remain sterile; so-called ‘probable 
bacterial infection’. In such cases, antibiotic therapy is 
usually continued intravenously, up to 7 days.6
In low-income and middle-income countries, the above 
practice is not common due to limited resources. The 
need for good home-based antibiotic treatment to 
reduce mortality following neonatal infections has led 
to several large randomised trials on the use of oral anti-
biotics. These studies showed that a simplified regimen 
with a switch to oral amoxicillin after 48 hours is as effec-
tive and safe as parenteral therapy.7–9 Results of those 
studies have been incorporated in WHO guidelines for 
the management of neonatal sepsis.10 Unfortunately, 
the outcomes cannot be applied to a higher income 
setting since the studies were based on clinical symp-
toms solely and no diagnostic tests were performed. 
This approach has not yet led to further research in 
high-income settings.
Several small studies have been published on the use 
of different oral antibiotics, evaluating both pharma-
cokinetics (PKs) and clinical efficacy. Regarding PKs, 
studies have commonly found that adequate antibiotic 
serum levels can be reached following oral administra-
tion, although peak levels are lower and appear later in 
time compared with parenteral administration. Further-
more, a great interindividual variation was seen.11 12 
Small efficacy studies evaluating an early-oral switch in 
neonates with a possible or proven infection are prom-
ising. In a cohort study, 222 infants with possible and 
proven group B streptococcal (GBS) infection switched 
to oral amoxicillin in a high dosage after 48 hours of 
intravenous treatment. During the 3-month follow-up 
period, no reinfections occurred.13 Similar results 
were found in a case–control study in which 36 infants 
with a possible or proven bacterial infection switched 
to oral cefpodoxime on day 3. No increase in reinfec-
tion rate was observed and the benefits of oral therapy 
included reduction of hospital stay and an increase 
in the number of exclusively breastfed newborns.13 14 
Unfortunately, study sizes were small and studies were 
not randomised. Furthermore, no full cost-effective-
ness analyses of paediatric intravenous-to-oral switch 
therapy have been reported to date. This represents 
an important knowledge gap, considering that, in the 
current era of austerity and rising healthcare costs, it 
is increasingly required to demonstrate whether or not 
new treatment strategies offer good value for money.
Together with uncertainties about bioavailability after 
oral administration, the lack of firm evidence delays 
further implementation in a high-resource setting. 
When intravenous-to-oral antibiotic switch therapy in 
neonatal infections is proven safe and effective, it can 
lead to a great improvement in quality of life (QOL) for 
both child and parents. Furthermore, it can reduce the 
length-of-hospital stay, which will have positive effects 
on rising healthcare costs.
objectives
The primary objective is to demonstrate non-inferiority 
of intravenous-to-oral antibiotic switch therapy in clin-
ically well neonates with a probable bacterial infection 
compared with a complete course of intravenous therapy. 
The secondary objectives are: (1) to describe PKs of oral 
amoxicillin/clavulanic acid in neonates; (2) to quan-
tify the cost-effectiveness of intravenous-to-oral switch 
therapy in neonates; (3) to evaluate the QOL in relation 
to switch therapy in neonates; (4) to study modification 
of the gut microbiome in relation to type and adminis-
tration of antibiotics and (5) to explore the additional 
value of molecular diagnostics on bacterial infection 
using left-over blood culture material that remains after 
culture time has passed.
MEthods And AnAlysIs
study design
The RAIN study (Reduction of intravenous Antibiotics In 
Neonates) is a multicentre, randomised controlled, open 
label, non-inferiority trial. Patients will be recruited in 17 
large teaching hospitals in the Netherlands. For details 
on participating hospitals, we refer to the online supple-
mentary material.
Participants
Neonates are eligible for participation if they have a post-
menstrual age of 35 weeks or more, are 0–28 days old, have 
a body weight of at least 2 kg and have a ‘probable bacte-
rial infection’ based on clinical symptoms or maternal risk 
factors and elevated inflammatory parameters for which 
the paediatrician has decided to complete a full course of 
intravenous antibiotics. A C reactive protein (CRP) level 
of ≥10 mg/L is considered as elevated. For procalcitonin 
(PCT), we refer to the age-adapted ranges.15 16 Clinical 
symptoms can be found in the online supplementary 
material. All neonates with a proven bacterial infection, 
for example, positive blood or cerebrospinal fluid culture 
or a severe clinical sepsis requiring intensive care treat-
ment are excluded from participation. Inclusion and 
exclusion criteria are described in table 1. Participants 
will be screened by the local paediatrician or investigator 
and randomised after 48 hours of intravenous treatment 
once informed consent has been obtained.
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Intervention
The intervention group will switch to oral amoxicillin/
clavulanic acid after 48 to 72 hours of intravenous antibi-
otics. The number of intravenous antibiotic doses prior 
to the switch will be recorded for every participant. The 
control group will receive the full course of intravenous 
antibiotics, which consists of penicillin and gentamicin, 
in case of early-onset sepsis, in most participating centres. 
Both groups will be treated for a total of 7 days. The trial 
flow diagram is outlined in figure 1.
Dosage, method of administration
A daily oral dose of 75/18.75 mg/kg of amoxicillin/
clavulanic acid, thus 25/6.25 mg/kg every 8 hours, will 
be administered. The mode of administration is orally 
via suspension, or in case of feeding problems (with the 
exception of vomiting) per nasopharyngeal tube. If the 
neonate vomits significantly within 30 min after adminis-
tration, the administration will be repeated.
randomisation and blinding
Participants will be randomised after 48 hours of intra-
venous treatment by a web-based programme according 
to a stratified block randomisation (stratified per site in 
alternated blocks of 2 and 4). Randomisation ratio will be 
1:1. Randomisation can under no circumstances be influ-
enced by the study team. If parents want their child to 
be in a specific group, they will be excluded from partic-
ipation. Patients and healthcare professionals will not be 
blinded, because of the nature of treatments (intravenous 
vs oral therapy); the primary investigators performing 
the statistical analysis will be blinded for the allocated 
treatment.
Follow-up
Neonates will only be discharged from the hospital if they 
have shown to tolerate the oral antibiotic treatment for at 
least two doses and are clinically well. Parents will be inter-
viewed by telephone on the first day after discharge and on 
day 14 after initiation of antibiotic therapy by the local study 
investigator or research nurse. The local investigator will 
assess antibiotic intake, signs of infection, side effects and 
events. In addition, parents will receive a survey on day 7 and 
day 21 with questions regarding possible signs of infection, 
side effects, QOL, loss of productivity, and cost-effectiveness 
and demographic data (maternal, paternal age, highest 
level of education, socioeconomic status and siblings). All 
surveys are available as online supplementary material. 
The primary outcome of the study is assessed 28 days after 
treatment completion, when the patient will be seen by 
the local investigator or research nurse for a final visit at 
the outpatient department. Parents of participants in the 
oral treatment group will be asked to return the bottle with 
remaining antibiotic suspension in order to evaluate medi-
cation adherence through measurement of the remaining 
amount of medication present in the bottle. Follow-up of 
neonates in the control group will be identical.
Power calculation
Relapse of proven GBS infection is estimated to occur 
in 0%–8% of patients, but may be caused by a different 
strain.17 Two epidemiological studies estimated the recur-
rence rate to be 1% in proven bacterial neonatal infec-
tions.18 19 The current study focuses on probable infections 
(in which the recurrence rate is likely even lower, although 
evidence for this is lacking). The incidence of communi-
ty-acquired late-onset sepsis in otherwise healthy neonates 
is low (~0.28 per 1000 live births).20 Therefore, we assume 
a 1% infection rate (including new non-related infections) 
in both groups. Based on a non-inferiority margin of 3% 
(minimum success rate 96%), 2×231 patients are needed 
for a power of 90% using a one-sided alpha of 0.025. 
Because of the first 30 patients undergoing PK measure-
ments and uncertainty about the PK values, and poten-
tial drop-out or withdrawal (estimated approximately 
5%–10%), we will include 2×275 neonates (total=550). A 
post hoc report on the design effect will be included.
data collection and management
Data will be collected by the local investigator at each 
site and stored anonymously in a Good Clinical Practice 
proof digital database (Castor EDC, Cewit B.V). Two inde-
pendent monitors will perform source data verification 
and assess performance of study procedures at each site 
following a predefined schedule.
outCoME MEAsurEs And stAtIstICAl AnAlysIs
Primary outcome 
The primary outcome is bacterial (re) infection within 
28 days after finishing antimicrobial therapy, defined 
Table 1 Inclusion and exclusion criteria Reduction of intravenous Antibiotics In Neonates study
Inclusion criteria Exclusion criteria 
 ► Neonates, postmenstrual age ≥35+0 weeks, postnatal age 
of 0–28 days, body weight ≥2 kg.
 ► Probable bacterial infection defined as clinical symptoms 
and/or maternal risk factors and elevated inflammatory 
markers for which empiric broad-spectrum antibiotic 
treatment was initiated and needs to be continued 
for >48 hours.
 ► Clinically well.
 ► Tolerate oral feeding without overt vomiting.
 ► Proven bloodstream infection.
 ► Absence of blood culture.
 ► Severe localised infection (meningitis, osteomyelitis, 
necrotising enterocolitis).
 ► Severe clinical sepsis (compromised circulation, need for 
mechanical ventilation).
 ► Continuous need for a central venous line.
 ► Severe hyperbilirubinaemia exceeding the exchange level.
 ► Parents’ inability to administer medication.
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as clinical symptoms of infection and fever (>38.0°C) 
or hypothermia (<36.0°C) and elevated inflammatory 
parameters with a need for prolonged antimicrobial 
therapy for more than 48–72 hours. Proven or suspected 
viral infection, for which no antibiotics are initiated or 
antibiotics are stopped within 48–72 hours (after return 
of culture and/or viral results) are not considered as 
a bacterial (re) infection. A chart will aid in decision 
making with respect to differentiation between bacte-
rial infection and other causes. Both per-protocol anal-
ysis and intention-to-treat analysis will be performed. A 
p<0.025 will be considered as significant. Regarding the 
primary outcome, 28-day cumulative bacterial infection 
rate; proportions will be defined and used to compare 
both treatment strategies. Subgroup analysis will be 
performed on late preterm neonates (gestational age 
35–37 weeks). Further, mixed-effect models will be used 
to take into account the multiple centres.
Interim analysis
A formal interim analysis will be performed after occur-
rence of the first four primary outcomes. The data safety 
Figure 1 Flow chart of study procedures. 1CRP, C reactive protein; PCT, procalcitonin; RAIN, Reduction of intravenous 
Antibiotics In Neonates.
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monitoring board (DSMB) will assess the results and it 
will be determined whether the occurrence of the primary 
outcome was related to the index suspected bacterial 
infection or more likely to be an unrelated infection. The 
outcome of that interim analysis will determine after how 
many primary outcomes the next interim analysis will be 
performed. When more than 75% of related cases occur 
in the intervention arm in two consecutive interim anal-
yses, the study will be stopped prematurely.
Secondary outcomes and their statistical analyses are 
described below.
secondary outcomes
Pharmacokinetics 
Blood samples of the first 30 patients treated with oral 
antibiotics (intervention arm) will be analysed in order 
to confirm that plasma concentrations are within target 
range and to endorse safety and dosing of the investi-
gated product. It is thought that time above the minimal 
inhibitory concentration (MIC) should be at least 
40%–50% in order for treatment with penicillins to be 
adequate.21 Therefore, T>MIC should be at least 50% in 
90% of the cases to be considered adequate, otherwise 
dosing needs to be adjusted. A target MIC of 8 mg/L is 
chosen for amoxicillin since this is the clinical breakpoint 
for Escherichia coli susceptibility defined by the European 
Committee on Antimicrobial Susceptibility (Eucast).22 
In a later stage, sampling will be continued in order to 
develop a pharmacokinetic/pharmacodynamic (PK/PD) 
model and to perform a population PK analysis. For the 
first 30 patients, two blood samples (0.5 mL whole blood) 
will be collected; the first sample 4–6 hours after the first 
or second dose, the second sample 6–8 hours after the 
second or third dose of oral suspension. In a subset of 
patients, we will collect two samples following the same 
administration in order to calculate an area under the 
curve. After the first analysis on samples from 30 patients, 
sampling will be continued through the collection of a 
single blood sample per patient. Samples will be handled 
within 1 hour after collection by the local laboratory. The 
sample will be centrifuged at 3000 rpm for 10 min and the 
recovered plasma will be stored at −80°C. Once enough 
samples have been collected for analysis, they will be 
shipped to the Erasmus MC for analysis. Serum concen-
trations of both amoxicillin and clavulanic acid will be 
measured. For each measurement, 50 μL of plasma is 
needed. Analysis will be performed batchwise combining 
both liquid chromatography and mass spectrometry. 
Analysis will be performed by descriptive statistics and by 
using non-linear mixed-effects modelling including vari-
ables such as timing of blood drawing, timing of last meal, 
patient weight, centre.
Molecular techniques for bacterial detection
Left over material of blood culture before initiation of anti-
biotic treatment will be stored at −80°C. Molecular anal-
ysis will be performed using next generation sequencing 
(NGS) methods, evaluating the additional yield of those 
techniques on bacterial detection compared with blood 
culture. Analysis will be performed batchwise, meaning 
that the additional value will be determined afterwards 
and that results will not be immediately available for the 
treating clinician nor for the DSMB in case of a (re)infec-
tion. However, results will be available at the end of the 
study and will be analysed in regard to primary outcomes 
that have occurred during the course of the study. The 
analysis of the NGS will initially be exploratory. If substan-
tial differences are noted in the yield of recovered organ-
isms from NGS compared with the blood culture, further 
analysis may be undertaken, exploring the relationship 
with clinical data such as inflammatory parameters and 
clinical illness. In that instance, mixed models will be 
used, and adjustments will be made for centre.
Gut microbiome
Microbiome alterations following antibiotic therapy, both 
in the intervention and control group, will be evaluated 
in 80 participants from four centres. Faecal samples will 
be collected at five different moments in the first year 
of life (around day 7, 30, 90, 180 and day 365) from 
neonates born vaginally. Samples will be collected from 
the diaper and immediately stored at −20°C in a special 
box placed in the home freezer. Parents will receive a 
notification at each sampling moment including a ques-
tionnaire regarding episodes of antibiotic treatment, 
type of feeding, daycare attendance and the presence of 
siblings at home. After 365 days, all samples will shipped 
to the central research locations and stored at −80°C until 
analysis in a specialised facility using high throughput 
sequencing targeted at the bacterial 16S rRNA locus. 
Alpha diversity of all samples will be calculated by the 
Shannon index. We will identify time points in which the 
alpha diversity and relative abundances in operational 
taxonomical units differ between the infants with intrave-
nous treatment and infants with intravenous-to-oral switch 
with a smoothing spline analysis of variance. Moreover, 
differences in the relative abundances of the genera will 
be tested with a linear mixed-effect model with correction 
for the variables of other antibiotic use, feeding type, day 
care attendance/sibling and centre.
Cost-effectiveness analysis
Following a superiority design, the cost-effectiveness anal-
ysis (CEA) will make a comparison between the interven-
tion and the control group by identifying, measuring and 
valuing the costs and patient outcomes of both treatment 
strategies.
Following established methods for economic evalua-
tions and costing studies in healthcare, both medical costs 
and non-medical costs (ie, costs of productivity losses) 
will be analysed for both study groups.23 24 Total medical 
costs over the 28-day follow-up period will be calculated, 
including costs of intravenous antibiotics, costs of oral 
antibiotics, laboratory costs and costs of hospitalisation 
days. In regard to readmission costs, only costs of a read-
mission for a bacterial (re) infection, as defined in the 
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outcome measures section, will be added to the analysis. 
Resource consumption will be derived from electronic 
hospital databases. Unit prices will be calculated using 
real economic cost prices or using standard cost prices 
for health economic evaluations. Unit prices will be multi-
plied by the quantities for each resource used, and then 
summed over the separate types of resource to give a total 
cost per patient. Then, productivity costs in the patients’ 
parents/caregivers, consisting of productivity losses 
regarding both paid and unpaid work, will be analysed 
(ignoring prearranged, regular maternity and paternity 
leave). These costs will be measured using the institute of 
Medical Technology Assessment Productivity Cost Ques-
tionnaire,25 completed by the parents during the sched-
uled follow-up as described above. The productivity costs 
will be valued following the friction cost method. Briefly, 
the valuation of paid work will be based on average hourly 
labour costs per paid employee, whereas that of unpaid 
work will be based on the replacement costs for house-
hold work. Finally, all costs will be summated for each 
individual patient.
Regarding the patient outcomes, the CEA will look at 
the number of bacterial (re) infections within 28 days 
after finishing of antimicrobial therapy. Building on the 
data on costs and outcomes described above, a cost-effec-
tiveness ratio will be calculated (the final endpoint of the 
CEA). This ratio will be expressed as incremental costs 
per bacterial (re)infection avoided. Otherwise, the CEA 
will focus on dominance of one treatment over the other 
with respect to lower cost and greater effect. Analysis of 
uncertainty in the estimation of the incremental cost-ef-
fectiveness ratio is illustrated through a cost-effectiveness 
plane (via bootstrapping). Where relevant, sensitivity 
analysis will be performed to assess the robustness of the 
analysis to certain assumptions.
Quality of life
To get an impression of the impact of an early intrave-
nous-to-oral antibiotic switch on the QoL of both parents 
and their child, parents will be asked to fill in a question-
naire on day 7 and day 21. Since there is no validated 
QoL instrument for neonates <1 month, we developed 
a questionnaire ourselves that collects information on 
total admission days and readmission rate, symptoms, 
side effects, amount of intravenous cannulas inserted 
during admission, sleep quality of the patient, number 
of medical visits and medication use in the first month, 
feeding and breastfeeding success rate and parents’ satis-
faction. Outcome reporting will be mainly descriptive, if a 
trend is observed for some of the questions, mixed-effect 
models can be used to further explore the effect of treat-
ment and centre.
safety consideration
Serious life events (SAEs) will be reported to the prin-
cipal investigator within 48 hours. The principal inves-
tigator will report the adverse events to the Medical 
Ethics Committee of the Erasmus Medical Centre and 
the Central Committee on Research Involving Human 
Subjects. All SAEs will be followed until they have abated, 
or until a stable situation has been reached. An indepen-
dent DSMB will be installed consisting of an epidemiolo-
gist/statistician, consultant neonatologist and paediatric 
infectious diseases specialist. The DSMB will evaluate the 
progress of the trial and will examine safety parameters at 
yearly intervals and through the performance of interim 
analyses when necessary. The adverse events will be listed 
and discussed with the DSMB.
Patient and public involvement
The Dutch parent organisation ‘Vereniging van Ouders 
van Couveusekinderen (VOC)’ was involved in the 
conceptualisation of the trial and has given their approval 
for the execution of this study. Patients will be asked at 
inclusion if they want to be informed on the final study 
results by email. Furthermore, a summary of findings will 
be published on the website of the VOC and on our own 
website.
dIssEMInAtIon
The results of the primary and secondary aims will be 
published in peer-reviewed journals and presented at 
international conferences, followed by a press release.
dIsCussIon/ConClusIon
Prolonged hospitalisation for intravenous therapy is still 
common practice in high-income societies when neonatal 
bacterial infection cannot be ruled out despite negative 
cultures. In-hospital treatment has a high impact on both 
patient and parents since prolonged hospitalisation often 
leads to infant–parent separation. Initiatives to prevent 
separation through the reduction of admission days 
are of increasing interest. The additional value of other 
biomarkers besides CRP, such as PCT, in order to rule 
out bacterial infection has been evaluated. A recent study 
showed that using PCT values as guidance for antibiotic 
therapy in neonates with a suspected bacterial infection 
leads to a reduction in days on therapy and hospitalisa-
tion. However, when the infection could not be ruled 
out, as is the case in infants with a probable infection, 
therapy was still continued intravenously for 7 days.26 We 
propose the first randomised controlled trial in a high-re-
source setting with a non-inferiority study design in 
order to demonstrate that oral antibiotic switch therapy 
is as effective as intravenous treatment in neonates with 
a probable bacterial infection. Furthermore, we will be 
the first to perform PK/PD analysis on oral amoxicillin/
clavulanic acid on a large sample size. Once proven that 
serum concentrations following oral administration are 
adequate, and non-inferiority of oral switch has been 
proven, oral switch therapy could potentially be expanded 
to clinically well infants with a proven infection.
This study has some limitations, the most important 
limitation relating to the primary outcome assessment. As 
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mentioned in the methods section, only neonates with a 
probable bacterial infection will be included. It is impos-
sible to state whether or not a second infection is a rein-
fection or that it is caused by a different pathogen. We, 
therefore, developed a list of recommended diagnostics 
that should be determined when a participant returns 
with signs of a possible infection. Those results can be 
used for correct and uniform assessment of the event and 
will help differentiating between a true bacterial infec-
tion, a probable bacterial infection or a viral infection.
Another limitation of the study relates to the fact 
that PK blood sampling will be performed in the inter-
vention group. As this procedure carries a small risk of 
infections, bias may be introduced into the study. On the 
other hand, patients in the control group are at risk for 
infection when replacement or new insertion of an intra-
venous cannula is needed. Both situations can lead to a 
possible bacterial infection. We think, however, that the 
infection risk is low when performed correctly including 
good hygiene measurements. Moreover, neonates in both 
groups are under antibiotic treatment which also covers 
Staphylococcus aureus.
Finally, bias may occur because of the oral treatment 
being administered out of the hospital setting. Since this 
treatment is home based, parents’ compliance in admin-
istering medication may be suboptimal, and we might 
underestimate the effectiveness of the intervention. In 
an attempt to overcome this limitation, infants will only 
be discharged when parents have shown to adequately 
administer the antibiotic suspension, parents will be 
phoned 1–2 days after discharge to evaluate medica-
tion administration, and parents will be asked to return 
the bottles with remaining antibiotic suspension at the 
final visit (which allows us to estimate the volume of the 
suspension actually administered).
We assume that once effectiveness and safety have been 
shown, implementation of intravenous-to-oral switch 
therapy will reduce the risks of hospital-related complica-
tions such as nosocomial infections and lead to an earlier 
return to a normal family setting with improvement in 
QOL and better mother–child bonding. Furthermore, we 
expect that the cost reduction will be substantial.
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